Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Enanta Pharmaceuticals (ENTA) Accumulated Depreciation & Amortization (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Accumulated Depreciation & Amortization readings, the most recent being $23.8 million for Q3 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 4.96% to $23.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $23.8 million, a 4.96% decrease, with the full-year FY2025 number at $23.8 million, down 4.96% from a year prior.
  • Accumulated Depreciation & Amortization hit $23.8 million in Q3 2025 for Enanta Pharmaceuticals, up from $22.5 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $25.2 million in Q2 2024 to a low of $18.9 million in Q3 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $22.5 million (2025), compared with a mean of $22.5 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: grew 20.75% in 2021 and later fell 10.67% in 2025.
  • Enanta Pharmaceuticals' Accumulated Depreciation & Amortization stood at $18.9 million in 2021, then grew by 15.49% to $21.9 million in 2022, then rose by 8.63% to $23.7 million in 2023, then dropped by 15.23% to $20.1 million in 2024, then increased by 18.26% to $23.8 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $23.8 million (Q3 2025), $22.5 million (Q2 2025), and $21.3 million (Q1 2025) per Business Quant data.